期刊文献+

3个项目联合检测胸腔积液的临床应用价值 被引量:1

暂未订购
导出
摘要 目的通过检测胸腔积液组织多肽抗原(TPA)、癌胚抗原(CEA)、神经元烯醇化酶(NSE),以探讨TPA同CEA、NSE联合检测在鉴别良恶性胸腔积液的临床价值。方法应用化学发光免疫分析法检测56例良性疾患组患者和72例恶性肿瘤组患者胸腔积液及血清TPA、CEA、NSE含量,并进行比较分析。结果恶性肿瘤组胸腔积液中TPA、CEA、NSE含量分别为(4175±2696.9)U/L,(198.7±237.9)ng/mL,(28.03±30.7)ng/mL均高于良性疾患组的(1123±656.2)U/L,(1.23±0.90)ng/mL,(8.10±8.36)ng/mL。良恶性胸腔积液之间三项肿瘤标志物差异具有统计学意义。并且恶性疾患组胸腔积液中三项标志物水平及诊断敏感性均显著高于三项肿瘤标志物血清。结论胸腔积液TPA、CEA、NSE检测有利于良恶性胸腔积液的鉴别,胸水三项肿瘤标志物比血清三项肿瘤标志物具有更重要的意义,三项标志物联合检测可以提高对肺癌诊断的灵敏度和特异性。
出处 《检验医学与临床》 CAS 2008年第6期346-347,共2页 Laboratory Medicine and Clinic
  • 相关文献

参考文献6

二级参考文献57

  • 1谢朝辉,袁昕.小细胞肺癌患者血清NSE检测的临床意义[J].中华肿瘤防治杂志,2001,12(z1):238-239. 被引量:3
  • 2齐法莲,杨道理,安娟,罗南萍,王波涛.多项血清学指标在肺癌患者中的应用价值[J].临床肿瘤学杂志,1998,3(3):9-11. 被引量:3
  • 3[1]Strauss GM, Skarin AT. Use of tumor markers in lung cancer.Hematol Oncol Clin North Am, 1994, 8(3) :507
  • 4[2]Jorgensen LG, Osterlind K, Genolla J, et al. Serum neuronspecific enolase (S-NSE) and the prognosis in small-cell lung cancer: A combined multivariable analysis on data from nine centers. BrJ Cancer, 1996, 74 (3) :463
  • 5[3]Jaques G, et al. Prognostic value of pretreatment carcinoembryonic antigens, neuron-specific enolase, and creatine kinase-BB levels in sera of patients with small cell lung cancer. Cancer,1988, 62 (1) : 125
  • 6[4]Johnson PW, Joel SP, Love S, et al. Tumor makers for prediction of survival and monitoring of remission in small cell lung cancer. BrJ Cancer, 1993, 67 (4) :760
  • 7[5]Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: An early predictor of complete response and survival in patients with small cell ling carcinoma. Cancer, 1998, 82 (6) :1049
  • 8[6]Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron specific enolase in squamous cell lung cancer patients.Clin Chem, 2002, 48 (11) :1931
  • 9[7]Brechot JM, Chevret S, Nataf, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumor markers in patients with NSCLS: A prospective study of 116 patients. Eur J Cancer, 1997, 33 (3) :385
  • 10[8]Koga H, et al. Preliminary evaluation of the new tumor marker,CYFRA 21-1, in lung cancer patients. Jpn J Clin Oncol,1994, 24 (5) :263

共引文献55

同被引文献12

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部